Skip to main content

Eli Lilly Canada Will Test MDS Proteomics Technology

NEW YORK, Jan. 14-Eli Lilly Canada will work with MDS Proteomics to evaluate PhosMap, an MDS technology that characterizes the changes in proteins that may develop during drug therapy.


Lilly will use the technology to assess the effects of kinase inhibitors on kinase targets. The collaboration is designed as a demonstration of the system.


Financial terms of the collaboration were not revealed. For further details, see the company website.


Eli Lilly Canada, headquartered in Toronto, is a division of Eli Lilly.


MDS Proteomics is a subsidiary of MDS.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.